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Efficacy of octreotide in diarrhoea 
due to Vibrio cholerae: a randomized, 
controlled trial 
BY Z. ABBAS, I. MOID, A. H. KHAN, S. M. W. JAFRI, 
S. H. A. SHAH, S. ABID AND S. HAMID 
Department of Medicine, The Aga Khan University Hospital, Stadium Road, 
P.O. Box 3500, Karachi 74800, Pakistan 
Received 19 December 1995, Revised 29 Febrtta7JI 1996, Accepted 4 March 1996 
Although octreotide, a long-acting analogue of somatostatin, is currently used in the treatment of chronic 
secretory diarrhoea due to various causes, its role in the management of acute secretory diarrhoea is not well 
established. In the present study, therefore, the therapeutic value of octreotide in the management of 
cholera, a classical example of acute secretory diarrhoea, was investigated. During an outbreak of cholera, 
patients admitted with acute secretory diarrhoea of ::;; 24 h duration and a purging rate >lOO ml/h were 
enrolled on the study and randomly assigned to octreotide (N= 17) and control (N= 16) groups. All 33 
patients received intravenous fluid replacement and antibiotic treatment (200 mg ofloxacin twice daily for 3 
days, by mouth). Each patient in the octreotide group was also given a subcutaneous injection containing 
lOO IJ.g octreotide every 8 h for a maximum of six doses. The stool output of each patient was recorded every 
hour until there had been none for an hour, which was taken as the endpoint. Mean (s.o.) total stool output 
was lower [6·56 (3·7) v. 9·7 (6·5) litres] and the mean (s.o.) duration of diarrhoea after admission was shorter 
[32·9 (15·6) v. 47·8 (22·3); P<O·OS] in the octreotide group than in the control group. However, as both 
groups generally had similar purging rates, the higher volume of stools from the control group was simply 
the result of the longer period of diarrhoea in this group. Octreotide therefore only decreased the duration 
of diarrhoea in the cholera patients. 
Vibrio cholerae is an important cause of watery 
diarrhoea all over the world (Spriggs and 
Richard, 1993). The organism remains in the 
intestinal lumen, does not invade the mucosal 
surface and secretes an enterotoxin which 
activates adenylate cyclase, resulting in the 
elevated concentration of cyclic AMP in 
the intestinal mucosa which is responsible for 
the increased intestinal secretion (Field et al., 
1989). There appears to be a differential action 
on mucosal cells, there being a direct secretory 
effect on the crypt cells (increased chloride 
secretion) and some anti-absorption effect on 
the villous cells for sodium and chloride (Fine 
et al., 1989). In addition, there is some evi-
dence that cholera toxin causes release of 
5-hydroxytryptamine; this stimulates the for-
mation of prostaglandin E2 and so activates 
small-bowel flux and secretion (Beugler et al., 
0003-4983/96/050507+07 $12.00/0 
1989). The magnitude of the small-bowel flux 
overwhelms the absorptive mechanism of the 
large bowel and large volumes of stools are 
produced. 
Cholera is a classical example of secretory 
diarrhoea where the balance between absorp-
tion and secretion of monovalent ions (Na +, 
K +, Cl- , HC03 -) is disturbed. The results 
of studies on the efficacy of treatment of 
various types of secretory diarrhoea with 
somatostatin and its long-acting analogue, 
octreotide, have been encouraging. These 
drugs have been used to treat chronic diar-
rhoea following ileostomy (Cooper et al., 
1986), the diarrhoea of tumours producing 
vasoactive intestinal polypeptide (Ruskone 
et al., 1982; Santangelo et al., 1985), carci-
noid (Oberg, 1993) and medullary thyroid 
carcmoma (Smid and Dullaart, 1992), 
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TABLE 1 
Clinical characteristics of the patients in the two study groups 
NO. OF PATIENTS 
Male 
Female 
All 
Mean (s.D.) age (years) 
MEAN (S.D.) DURATION OF DIARRHOEA (h) 
Pre-admission 
Post -admission 
Octreotide 
7 
10 
17 
43-4 (17·5) 
18·5 (7·0) 
32·9 (15·6) 
Control 
7 
9 
16 
43·2 (17-4) 
16·1 (6·9) 
47-8 (22·3)* 
Mean (s.D.) total stool volume post-admission 
(litres) 6·56 (3·7) 9·7 (6·5) 
*P<O·OS. 
TABLE 2 
Results of laborat01J! tests of the patients at the start of the study 
MEAN (S.D.) RESULTS OF BLOOD TESTS 
Blood urea nitrogen (mM) 
Serum creatinine (J.lM) 
Random blood sugar (mM) 
Serum sodium (mM) 
Serum potassium (mM) 
Serum chloride (mM) 
Serum bicarbonate (mM) 
MEAN (S.D.) RESULTS OF STOOL TESTS 
Sodium (mM) 
Potassium (mM) 
Chloride (mM) 
Bicarbonate (mM) 
Stool osmolality (mOsm/kg) 
AIDS-related diarrhoea (Manfredi et al., 
1993), short-bowel syndrome (Rosen, 1992), 
dumping syndrome (Lamers et al., 1993) and 
diabetic diarrhoea (Mourad et al., 1992; 
Walker and Kaplan, 1993). Octreotide has 
been used in these studies in doses of 50-
lOO f..lg, given subcutaneously every 8-12 h. 
The role of octreotide in the management of 
acute secretory diarrhoea has not been exten-
sively studied. The efficacy of this agent in 
Octreotide group 
H (1·5) 
221·0 (141-4) 
10·1 (3·1) 
137·5 (5·7) 
4·1 (1·0) 
107-6 (H) 
8·8 (3-8) 
127·5 (18·9) 
21·1 (8·0) 
113·3 (19·2) 
27·5 (8·1) 
278·6 (47·5) 
Control group 
2·9 (0·6) 
185-6 (79·6) 
9·9 (2·1) 
136·0 (3-6) 
4·1 (0·6) 
107-1 (3-3) 
8·8 (4·3) 
130·1 (16·6) 
19·8 (8·4) 
115·4 (16·1) 
22·8 (10·5) 
278·9 (19· 5) 
acute secretory diarrhoea due to Vibrio cholerae 
was therefore investigated. 
PATIENTS AND METHODS 
Patients complaining of acute watery diarrhoea 
who were admitted during the summer to the 
Medical Unit of The Aga Khan University 
Hospital, Karachi, Pakistan, were enrolled on 
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TABLE 3 
Purging rates (m// h) of the 'on stud)" patimts 
Time Octreotide group Control group 
post-admission 
(h) N Mean rate and ( s.E.) N ;\!Jean rate and (s.E.) 
0 17 262·0 (25·2) 16 229·0 (32·0) 
DAY 1 
0-4 17 271·1 (28·8) 16 292·5 (37-4) 
5-8 17 247·3 (27-6) 16 252·2 (30·8) 
9-12 16 228· 5 (22· 3) 16 235·1 (58·8) 
13-16 15 234·6 (35·2) 15 222·2 (30-4) 
17-20 15 246·8 (32·1) 15 218·1 (32·8) 
21-24 13 204-6 (18·1) 15 201-4 (25·5) 
DAY 2 
0-4 13 134-4 (18·9) 14 201·1 (23-6) 
5-8 11 120·3 (16·5) 14 177-2 (25·3) 
9-12 10 116·1 (21·6) 14 142·7 (25·6) 
13-16 6 162·3 (18·4) 11 164·1 (42-4) 
17-20 6 124·8 (24-9) 8 203·1 (70·8) 
21-24 5 92·4 (22·7) 7 157·0 (28·6) 
DAY 3 
0-4 4 79· 5 (17-9) 6 170·7 (32·8) 
5-8 3 83·3 (33·9) 5 191·0 (37·7) 
9-12 1 87 5 170·0 (21·6) 
13-16 1 60 5 125·0 (28·6) 
17-20 0 4 87·2 (13-5) 
21-24 0 3 87·3 (32·1) 
DAY 4 
0-4 0 206·0 
5-8 0 175·0 
9-12 0 162·0 
13-16 0 150·0 
17-20 0 125·0 
20-24 0 62·0 
the study, which was approved by the Ethics 
Committee of the hospital. Eligibility criteria 
were acute secretory diarrhoea of ~ 24 h dur-
ation and a persistent purging rate > 100 ml/h 
during the first 8 h post-admission. Children, 
pregnant women, patients suffering from other 
concurrent illness and patients who had re-
ceived antimicrobial or antidiarrhoeal agents 
before presentation were excluded. Informed 
consent was obtained before the patients were 
randomly assigned to the treatment group or 
the control group. All patients received stan-
dard supportive care, including intravenous 
fluid replacement, until there had been no 
stool output for an hour, and antibiotic treat-
ment by mouth (200 mg ofloxacin twice daily 
for 3 days). Each patient in the treatment 
group was also given octreotide by subcu-
taneous injection for 40 h or until there had 
been no stool output for an hour, if this 
occurred sooner: 100 J.lg (0· 5 m!) every 8 h. 
On presentation, the hydration state of each 
patient was assessed from the changes in pulse 
and blood pressure that occurred as the patient 
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Fig. 1. The decrease in the numbers of patients 'on 
study' (i.e. producing stools every hour) in the 
treatment (e) and control ( •) groups. 
changed posture. Routine tests comprised 
complete blood counts, blood urea nitrogen, 
creatinine and electrolytes. Stools were exam-
ined and sampled for culture to check whether 
Vibrio choleme was present and to determine 
electrolyte concentrations and osmolarity. 
The secretory nature of the diarrhoea in each 
patient was defined by the osmotic gap (i.e. the 
difference between stool osmolality measured 
directly and that estimated as twice the com-
bined concentrations of N a+ and K + ); this was 
always :(40 mOsm. Hourly stool outputs were 
subsequently measured using rectal catheters 
(22F Foley's) connected to urine bags; an 
empty bag at the end of a 1-h sampling period 
was taken as the end point of the study for each 
patient. 
Statistical Analysis 
All statistical analyses were made using com-
mercial software (Epi-Info). One-way analysis 
of variance was used for normally distributed 
data. Homogeneity of variance was checked 
with Bartlett's test, Mann-Whitney tests were 
used for samples with unequal standard 
deviations and Fisher's exact tests were used 
for comparison of discrete variables. 
RESULTS 
Overall, 35 patients were initially enrolled in 
the study, 18 of whom were given octreotide. 
However, two patients, one from each group, 
were excluded from the final analysis as Vibrio 
cholerae could not be detected in their stool 
cultures. The two groups were similar in terms 
of patient age and sex and the durations of 
diarrhoea before admission (Table 1) and in 
terms of their basal concentrations of blood 
urea nitrogen, creatinine, random blood sugar, 
serum electrolytes and stool electrolytes and 
osmolarity (Table 2). The mean (s.o.) duration 
of diarrhoea post-admission (Table 1) was 
shorter in the octreotide group than in 
the control group [32·9 (15·6) v. 47·8 (22· 3 h); 
P=0·03]. The one member of the control 
group who had diarrhoea for > 3 days (i.e. 4 
days) accounted for much of the difference; if 
the result for this patient is excluded, the mean 
duration of diarrhoea for the remaining con-
trols decreases to 44·6 (18·8) h and the signifi-
cance of the difference from the result for the 
treatment group also decreases (P=0·06). 
Mean (s.o.) total stool output was less for the 
treatment group [6· 56 (3·7) litres] than for the 
controls [9·7 (6·5) litres]. At any particular 
time after the first 8 h, the number of 'on 
study' patients (i.e. those still producing stools 
every hour) was less in the octreotide group 
than in the control group, though the differ-
ence was never statistically significant (Table 
3, Figs 1 and 2). Purging rates (ml/h) for those 
'on study' were always the same for the two 
groups except at 28 h (P=0·04) (Table 3). 
However, pooled purging rates (ml/ day) were 
significantly lower in the treatment group on 
day 3 than in the controls (P=0·04). No side 
effects were noticed by any of the patients 
receiving octreotide. 
DISCUSSION 
The mechanism of secretory diarrhoea in chol-
era is complex. The cholera toxin activates 
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Fig. 2. Changes in purging rates with time in (a) the treatment group and (b) the control group. 
adenylate cyclase (AC), a bound enzyme that 
is complexed through stimulatory (Gs) and 
inhibitory (Gi) G proteins (Gilman, 1984). In 
enterocytes, AC is located exclusively in the 
basolateral membrane and is stimulated when 
the cholera toxin activates Gs; the activated a, 
subunit of Gs protein dissociates from the rest 
of the apical-membrane-bound molecule and 
attaches to the catalytic subunit of AC in the 
basolateral membrane, activating the enzyme 
(Field et al., 1989). Somatostatin inhibits 
enterocyte AC activity by a cholera-toxin-
insensitive, pertussis-toxin-sensitive Gi pro-
tein (Reyl-Desmars et al., 1986). Cholera toxin 
also causes release of 5-hydroxytryptamine, 
stimulating the formation of prostaglandin E2 
(Beubler et al., 1989). Prostaglandins of the E 
series in turn increase water and electrolyte 
secretion via the activation of AC (Kimberg 
et al., 1971). Somatostatin has also been shown 
512 ABBAS ET AL. 
to inhibit this activation m an animal model 
(Pawlotsky et al., 1993). 
Although Fedorak and Alien (1989) failed to 
show any alteration m cholera-toxin-
stimulated secretion in rats given somatostatin 
analogue, Yoshioka et al. (1987) had earlier 
reported the effectiveness of somatostatin in 
the treatment of cholera-induced, secretory 
diarrhoea in rats. Yoshioka et al. (1987) found 
that the drug had a suppressive effect on the 
diarrhoea and inhibited the appearance of 
glyco-enzymes in the intestinal lumen and 
lymph production induced by the admin-
istration of cholera toxin but did not affect the 
elevated cAMP concentration. They postu-
lated that the drug exerts its inhibitory effect 
beyond cAMP formation. It is possible that 
octreotide also fails to alter existing cAMP and 
that its effectiveness depends on some other 
mechanism. The results of a study by Sjoqvist 
(1992) demonstrated the anti-secretory effect 
of octreotide in anaesthetized rats and were 
consistent with octreotide inhibiting the 
nervous secretomotor reflex activated by the 
cholera toxin. cAMP induced by cholera toxin 
may serve as a physiological mediator for 
acetylcholine release from myenteric plexus 
neurons. Somatostatin inhibits release of 
acetylcholine evoked by various cAMP agon-
ists in a dose-dependent manner (Wiley and 
Owyang, 1987). Octreotide has been shown to 
increase jejuna! transit time (Dueno et al., 
1987). Somatostatin hyperpolarizes the sub-
mucous plexus neurons of guinea-pig by in-
creasing the conductance of a set of inwardly 
rectifying potassium channels; this hyper-
polarization is unaffected by cholera toxin 
(Mihara et al., 1987). 
Molla et al. (1984) assessed the ability 
of somatostatin to reduce the stool out-
put of cholera patients in a double-blind, 
randomized, controlled trial. In this study, 
the drug was given for 12 h in a continuous 
infusion, was followed by a 12-h obser-
vation period and had no apparent effect 
on output when compared with control 
values from patients given placebo. How-
ever, the number of patients studied was 
small, the drug was given over a relatively 
short period and the follow-up period was 
also short, ending while the patients still 
had diarrhoea. Although the present results 
indicate that octreotide had little effect on 
purging rates, the drug did reduce the total 
duration of diarrhoea significantly. It may 
be that the persistent activity of this long-
acting analogue of somatostatin overcomes 
the secreting factors and eventually shifts 
the balance in favour of diarrhoea-inhibiting 
mechanisms. 
What are the therapeutic implications of this 
study? Should we include octreotide in future 
regimens of cholera treatment? Diarrhoea was 
arrested 14·9 h earlier by adding this expensive 
drug to the usual hydration and antibiotic 
therapy. Although this improvement may not 
make much difference in otherwise healthy 
adults, it could be much more significant in the 
treatment of the young and the elderly. The 
study could not be continued further because 
the outbreak of cholera which produced the 
influx of patients who were subsequently en-
rolled ended. A larger randomized trial using 
higher dosages may further clarify the role of 
octreotide in the management of secretory 
diarrhoea due to cholera. 
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